- Home
- UBSI vs BPMC Comparison
UBSI vs BPMC Comparison
Compare UBSI & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBSI
- BPMC
- Stock Information
- Founded
- UBSI 1982
- BPMC 2008
- Country
- UBSI United States
- BPMC United States
- Employees
- UBSI N/A
- BPMC N/A
- Industry
- UBSI Major Banks
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- UBSI Finance
- BPMC Health Care
- Exchange
- UBSI Nasdaq
- BPMC Nasdaq
- Market Cap
- UBSI 5.3B
- BPMC 5.8B
- IPO Year
- UBSI N/A
- BPMC 2015
- Fundamental
- Price
- UBSI $35.71
- BPMC $127.71
- Analyst Decision
- UBSI Hold
- BPMC Buy
- Analyst Count
- UBSI 4
- BPMC 18
- Target Price
- UBSI $40.13
- BPMC $125.88
- AVG Volume (30 Days)
- UBSI 544.8K
- BPMC 789.4K
- Earning Date
- UBSI 07-24-2025
- BPMC 05-01-2025
- Dividend Yield
- UBSI 4.09%
- BPMC N/A
- EPS Growth
- UBSI 2.88
- BPMC N/A
- EPS
- UBSI 2.70
- BPMC N/A
- Revenue
- UBSI $1,021,155,000.00
- BPMC $562,121,000.00
- Revenue This Year
- UBSI $20.15
- BPMC $44.49
- Revenue Next Year
- UBSI $5.19
- BPMC $33.04
- P/E Ratio
- UBSI $13.41
- BPMC N/A
- Revenue Growth
- UBSI 0.82
- BPMC 99.19
- 52 Week Low
- UBSI $30.51
- BPMC $73.04
- 52 Week High
- UBSI $44.43
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- UBSI 47.95
- BPMC 76.43
- Support Level
- UBSI $35.95
- BPMC $94.38
- Resistance Level
- UBSI $36.88
- BPMC $102.52
- Average True Range (ATR)
- UBSI 0.63
- BPMC 3.48
- MACD
- UBSI -0.18
- BPMC 1.30
- Stochastic Oscillator
- UBSI 8.33
- BPMC 98.15
About UBSI United Bankshares Inc.
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which accepts deposits, makes loans (for personal, credit card, commercial, and construction uses), provides brokerage services, safe deposit boxes, and related services.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.